MBBS, MD UNSW, FRACP

Professor Glenn Marshall has been Head of the Molecular Carcinogenesis Program at CCIA since 1995. His primary preclinical research interests include investigating the mechanisms by which normal embryonal cells become cancerous, and improving the effectiveness of non-cytotoxic anti-cancer therapy in child cancer.

Professor Marshall has a longstanding clinical and translational research focus on relapse detection by Minimal Residual Disease (MRD) testing in leukaemia, and the therapy of high-risk or relapsed leukaemia. He was instrumental in the genesis of the current national study of children with acute lymphoblastic leukaemia (ALL), conducted by the Molecular Diagnostics Program, which has applied MRD testing to individualise therapy in ALL. He is currently co-chair of the Australian and New Zealand Children’s Haematology and Oncology Group (ANZCHOG) ALL Study VIII.

In addition to his research activities, Professor Marshall is a full-time paediatric haematologist and oncologist, and Director of the Centre for Children's Cancer and Blood Disorders at Sydney Children's Hospital, Randwick. He has authored more than 75 papers in peer-reviewed scientific journals.

In 2011. Professor Marshall was appointed Head of Translational Research at CCIA.